Literature DB >> 32763509

Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis.

Danielle Richards1, John A Morren2, Erik P Pioro3.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, degenerative neuromuscular disease with limited treatment options. The diagnosis of ALS can be challenging for numerous reasons, resulting in delays that may compromise optimal management and enrollment into clinical trials. Several studies have examined the process and challenges regarding the clinical diagnosis of ALS. Twenty-one studies that were almost exclusively from the English literature published between 1990 and 2020 were identified via PubMed using relevant search terms and included patient populations from the United States, Canada, Japan, Egypt, and several countries in South America and Europe. Probable or definitive ALS patients were identified using El Escorial or revised El Escorial/Airlie House Criteria. Time to diagnosis or diagnostic delay was defined as mean or median time from patient-reported first symptom onset to formal diagnosis by a physician, as recorded in medical records. The typical time to diagnosis was 10-16 months from symptom onset. Several points of delay in the diagnosis course were identified, including specialist referrals and misdiagnoses, often resulting in unnecessary procedures and surgeries. Bulbar onset was noted to significantly reduce time to ALS diagnosis. Future interventions and potential research opportunities were reviewed.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Diagnostic delay; Motor neuron disease; Time to diagnosis

Mesh:

Year:  2020        PMID: 32763509     DOI: 10.1016/j.jns.2020.117054

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Identifying key signs of motor neurone disease in primary care: a nested case-control study using the QResearch database.

Authors:  Xue W Mei; Judith Burchardt; Tom A Ranger; Christopher J McDermott; Aleksandar Radunovic; Carol Coupland; Julia Hippisley-Cox
Journal:  BMJ Open       Date:  2022-06-28       Impact factor: 3.006

2.  Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy.

Authors:  Giulia Gianferrari; Ilaria Martinelli; Elisabetta Zucchi; Cecilia Simonini; Nicola Fini; Marco Vinceti; Salvatore Ferro; Annalisa Gessani; Elena Canali; Franco Valzania; Elisabetta Sette; Maura Pugliatti; Valeria Tugnoli; Lucia Zinno; Salvatore Stano; Mario Santangelo; Silvia De Pasqua; Emilio Terlizzi; Donata Guidetti; Doriana Medici; Fabrizio Salvi; Rocco Liguori; Veria Vacchiano; Mario Casmiro; Pietro Querzani; Marco Currò Dossi; Alberto Patuelli; Simonetta Morresi; Marco Longoni; Patrizia De Massis; Rita Rinaldi; Annamaria Borghi; Amedeo Amedei; Jessica Mandrioli
Journal:  Biomedicines       Date:  2022-03-31

3.  Prediction Model of Amyotrophic Lateral Sclerosis by Deep Learning with Patient Induced Pluripotent Stem Cells.

Authors:  Keiko Imamura; Yuichiro Yada; Yuishin Izumi; Mitsuya Morita; Akihiro Kawata; Takayo Arisato; Ayako Nagahashi; Takako Enami; Kayoko Tsukita; Hideshi Kawakami; Masanori Nakagawa; Ryosuke Takahashi; Haruhisa Inoue
Journal:  Ann Neurol       Date:  2021-02-25       Impact factor: 10.422

4.  Early and progressive dysfunction revealed by in vivo neurite imaging in the rNLS8 TDP-43 mouse model of ALS.

Authors:  Akram Zamani; Adam K Walker; Ben Rollo; Katie L Ayers; Raysha Farah; Terence J O'Brien; David K Wright
Journal:  Neuroimage Clin       Date:  2022-04-22       Impact factor: 4.891

Review 5.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

6.  Role of plasma phosphorylated neurofilament heavy chain (pNfH) in amyotrophic lateral sclerosis.

Authors:  Chiara Zecca; Maria Teresa Dell'Abate; Giuseppe Pasculli; Rosa Capozzo; Roberta Barone; Serena Arima; Alessio Pollice; Vincenzo Brescia; Rosanna Tortelli; Giancarlo Logroscino
Journal:  J Cell Mol Med       Date:  2022-06-17       Impact factor: 5.295

Review 7.  Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?

Authors:  Bradley Roberts; Frances Theunissen; Francis L Mastaglia; P Anthony Akkari; Loren L Flynn
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

8.  Neuroprotective Effect of Sonic Hedgehog Mediated PI3K/AKT Pathway in Amyotrophic Lateral Sclerosis Model Mice.

Authors:  Yan Qi; Chen Yang; Hui Zhao; Zhanjin Deng; Jin Xu; Weijing Liang; Zhitang Sun; John Dirk Vestergaard Nieland
Journal:  Mol Neurobiol       Date:  2022-09-03       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.